News
Eli Lilly CEO David Ricks bought just over $1 million of Lilly shares in the open market Tuesday following the sharp drop in ...
Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...
Eli Lilly specializes in obesity and diabetes treatments, among other areas. It's reasonable to expect a lot more growth from ...
12h
TipRanks on MSNEli Lilly’s Orforglipron Study: A New Hope for Obesity Treatment?
Eli Lilly And Company (($LLY)) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company recently completed a ...
The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...
The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity ...
Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...
More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...
16h
Global News - Inquirer.net on MSNWill China’s home-grown obesity drugs reshape global weight loss market?
July, video editor Meng Meng, 38, has been injecting herself with a weekly weight loss drug, hoping it will finally help her shed the weight she has long struggled with. Standing at 1.63m tall and ...
8h
Medpage Today on MSNGLP-1 Maker Accused of Bribing Docs; FDA Warns on Unapproved Meds; PFAS in Devices
The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results